JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Akiyama, K.
Right arrow Articles by Kitazawa, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Akiyama, K.
Right arrow Articles by Kitazawa, M.

Vol. 291, Issue 1, 81-91, October 1999

KMD-3213, a Uroselective and Long-Acting alpha 1a-Adrenoceptor Antagonist, Tested in a Novel Rat Model

Katsuyoshi Akiyama, Masachiyo Hora, Satoshi Tatemichi, Naoyuki Masuda, Syunji Nakamura, Ryoichi Yamagishi and Makio Kitazawa

Central Research Laboratories, Kissei Pharmaceutical Co., Ltd., Kashiwabara, Hotaka, Minamiazumi, Nagano, Japan

KMD-3213, an alpha 1a-adrenoceptor (AR) antagonist, is under development for the treatment of urinary outlet obstruction in patients with benign prostatic hypertrophy. In the present study, we developed a rat model to investigate simply the effects of alpha 1-AR antagonists on the intraurethral pressure (IUP) response to phenylephrine. Using this model, inhibitory effects of both i.v. and intraduodenally administered KMD-3213 on the IUP response were evaluated and compared to those of other reference compounds, including prazosin and tamsulosin. In addition, the hypotensive effects of these compounds were estimated to evaluate uroselectivity. Intravenously administered alpha 1-AR antagonists tested, including KMD-3213, potently inhibited the IUP response in a dose-dependent manner. Although the higher doses of those compounds almost completely inhibited the IUP response, yohimbine failed to inhibit the response. When the in vivo potencies of those compounds on IUP response were correlated with their affinities for the human or animal recombinant alpha 1-AR subtypes, alpha 1a-AR gave the best correlation. In this model, KMD-3213 had greater uroselectivity than any other compounds examined, by both i.v. and intraduodenal routes. Moreover, 12, 18, and 24 h after the oral administration of KMD-3213, a dose-dependent inhibition of the IUP response was found, whereas the effect of tamsulosin disappeared at 18 h after the oral administration. These data indicate that KMD-3213 is a highly uroselective alpha 1-AR antagonist with a longer duration of action. In addition, this model is useful for not only estimation of uroselectivity but also some part of the administration, distribution, metabolism, and excretion of many compounds to discover uroselective compounds.


0022-3565/99/2911-0081$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1999 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
Y. P. R. Jarajapu, F. Johnston, C. Berry, A. Renwick, J. C. McGrath, A. MacDonald, and C. Hillier
Functional Characterization of alpha 1-Adrenoceptor Subtypes in Human Subcutaneous Resistance Arteries
J. Pharmacol. Exp. Ther., November 1, 2001; 299(2): 729 - 734.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
S. Yamada, T. Okura, and R. Kimura
In Vivo Demonstration of {alpha}1A-Adrenoceptor Subtype Selectivity of KMD-3213 in Rat Tissues
J. Pharmacol. Exp. Ther., January 1, 2001; 296(1): 160 - 167.
[Abstract] [Full Text]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1999 by the American Society for Pharmacology and Experimental Therapeutics.